Urology Times staff

Figlin shares his expert observations on important questions that still remain, despite the positive results of the trial.

In this video, Ranjith Ramasamy, MD, explains that although testosterone therapy comes with risks, “these risks appear to be very, very small.”

Neal D. Shore, MD, discusses results from the phase 2 ODENZA trial which explored patient preference between darolutamide and enzalutamide in men with metastatic castration-resistant prostate cancer.

In this video, lead author Edmund M. Qiao discusses study results presented during the 2021 ASCO Annual Meeting which showed an association between increased prostate-specific antigen screening and improved outcomes in younger African American patients.

“Patients of African ancestry were actually less likely to receive comprehensive genomic profiling earlier in their treatment course than patients of European ancestry, and…patients of African ancestry [were] less likely to be treated in clinical trials,” says Jessica Lee, MS.

“Recurrence of urothelial cancer, in particular metastatic recurrence, is associated with a detriment in quality of life in this exploratory analysis,” says Matthew Galsky, MD.

Nizar M. Tannir, MD, discusses results from the phase 2 CANTATA study of cabozantinib plus telaglenastat in patients with advanced/metastatic renal cell carcinoma.

Neeraj Agarwal, MD, discusses results from the phase 3 SWOG S1216 trial, which compared ADT plus the novel agent TAK-700 or bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer.

Darolutamide is FDA-approved for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

“It could be that the integration of a new treatment modality into the bladder-sparing arena is a tipping point that is needed to really have the community embrace this as a reasonable option for patients with bladder cancer,” says Matthew Galsky, MD.

Mark Christopher Markowski, MD, PhD, discusses phase 1b/2 data for the novel oral cytoskeletal disruptor VERU-111 in metastatic castration-resistant prostate cancer being presented during the 2021 ASCO Annual Meeting.

Robert J. Motzer, MD, discusses how the outcomes of the phase 3 CLEAR trial impact the use of pembrolizumab/lenvatinib in patients with renal cell carcinoma.

Neeraj Agarwal, MD, discusses health-related quality of life and patient-reported outcomes from the phase 3 TITAN trial of apalutamide in patients with metastatic castration-sensitive prostate cancer.

Viktor Grünwald, MD, discusses a subanalysis of the phase 3 CLEAR trial.

Agarwal also discusses the ongoing phase 3 randomized CONTACT-02 study.

“We had a very low rate of nonattendance amongst oncology appointments, as compared to some other appointments,” says Randie White, MD.

“There is a lot of debate about the final shape and form of what telemedicine should look like,” says Chad Ellimoottil, MD, MS, in this video.

In Urology Times’ monthly installment of Around the Practice, experts discuss adverse event management from various treatments for prostate and bladder cancer.

In Urology Times’ monthly installment of Around the Practice, experts discuss adverse event management from various treatments for prostate and bladder cancer.

In Urology Times’ monthly installment of Around the Practice, experts discuss adverse event management from various treatments for prostate and bladder cancer.

Jason Zhu, MD, discusses how next-generation imaging is critical to advancing personalized medicine in prostate cancer.

In this video, Jennifer M. Taylor, MD, MPH, also shares one of her strategies to cope with burnout and provides advice for others struggling with burnout.

Ranjith Ramasamy, MD, explains how the oral testosterone capsule Jatenzo works and touches on key findings from a recent study of the treatment.

“I think doctors should be aware that if men do complain of erectile dysfunction after [having] COVID-19 that it could be because of underlying endothelial dysfunction and underlying vasculature issues,” Ramasamy says.

“We really found it surprising the sheer amount of debt that our urology trainees are carrying,” Harris said.

“We found that there is going to be a significant proportion of growth in the urology work force related to the number of women in urology, which is really exciting,” says Kate H. Kraft, MD.

The PARP inhibitors olaparib and rucaparib are approved by the FDA for prostate cancer and other PARP agents are moving through the pipeline.

Ellimoottil also discusses the status of his own practice with regards to in-person vs telemedicine visits.

“Speak out. speak out. If you're a physician who's going through a hard time, I can promise you you're not alone,” says Raj S. Pruthi, MD, MHA, FACS.

“I really fell in love with [urology] from the get go,” Kraft says.